BLA 020898 · Genzyme
Thyrogen
Thyrotropin Alfa · Injection · Thyroid Stimulating Hormone
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 12, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Nov 30, 1998
Approved uses
5
Original approval plus efficacy supplements
Registered trials
86
18 Phase 3, 8 recruiting
FAERS reports
1,038
353 serious, 23 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 24, 2023.
THYROGEN ® is a thyroid stimulating hormone indicated for: Adjunctive Diagnostic Tool for Well-Differentiated Thyroid Cancer: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. ( 1.1 ) Limitations of Use : THYROGEN-stimulated Tg levels are generally lower than, and do not correlate with Tg levels after thyroid hormone withdrawal. Even when THYROGEN-Tg testing is performed in combination with radioiodine imaging, there remains a risk of missing a diagnosis of thyroid cancer or underestimating the extent of the disease. Anti-Tg Antibodies may confound the Tg assay and render Tg levels uninterpretable. Adjunct for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer: Use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer. ( 1.2 ) Limitations of Use : The effect of THYROGEN on thyroid cancer recurrence greater than 5 years post-remnant ablation has not been evaluated. 1.1 Adjunctive Diagnostic Tool for Well-Differentiated Thyroid Cancer THYROGEN ® is indicated for use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. Limitations of Use : THYROGEN-stimulated Tg levels are generally lower than, and do not correlate with, Tg levels after thyroid hormone withdrawal [see Clinical Studies (14.1) ] . Even when THYROGEN-stimulated Tg...
Mechanism: Thyrotropin (TSH) is a pituitary hormone that stimulates the thyroid gland to produce thyroid hormone. Binding of thyrotropin alfa to TSH receptors on normal thyroid epithelial cells or on well-differentiated thyroid cancer tissue stimulates iodine uptake and organification, and synthesis and secretion of thyroglobulin (Tg), triiodothyronine (T3) and thyroxine (T4). The effect of thyroid stimulating hormone activation of thyroid cells is to increase uptake of radioiodine to allow scan detection or radioiodine killing of thyroid cells. TSH activation also leads to the release of thyroglobulin...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 12, 2020 Supplement 65 · Efficacy OrphanLetterLabel
- Mar 21, 2014 Supplement 54 · Efficacy LetterLabel
- Dec 14, 2007 Supplement 29 · Efficacy · priority review LabelLetter
- Jan 24, 2006 Supplement 31 · Efficacy LabelLetter
- Nov 30, 1998 Original approval · Type 1 - New Molecular Entity · priority review OtherReviewLetter
1 products under this application
- THYROGEN · THYROTROPIN ALFA 1.1MG/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Thyrotropin Alfa" as an intervention, any sponsor and status, largest first.
- A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00696800 · 1,509 participants · Start Jun 27, 2006 · Primary completion Nov 19, 2007
Drug: Corifollitropin alfa; RecFSH / Follitropin beta (Days 1 to 7) and 6 more · For: In Vitro Fertilization
- Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVFPivotal-lookingCompleted
Fertility Biotech AGIndustry
NCT01687712 · 1,100 participants · Start Nov 25, 2013 · Primary completion Sep 10, 2015
Drug: AFOLIA; Gonal-f® RFF · For: Infertility
Sites: Tempe, Arizona; Encino, California; Newark, Delaware · 22 sites in all
- Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma PatientsPivotal-lookingStatus unknown
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT00435851 · 950 participants · Start Feb 2007
Drug: Thyrogen, thyroid hormone withdrawal, iode 131 · For: Thyroid Cancer
Sites: Villejuif, France
Lund UniversityAcademic, hospital or other
NCT03737253 · 810 participants · Start Sep 2016 · Primary completion Dec 31, 2021
Drug: Follitropin alpha; Menotropin · For: Female Infertility
Sites: Poznan, Poland; Malmö, Sweden
- Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?Pivotal-lookingActive, not recruiting
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT01837745 · 776 participants · Start May 13, 2013 · Primary completion Apr 1, 2022
Drug: rhTSH stimulation; I131 · For: Low Risk Differentiated Thyroid Cancer
Sites: Villejuif, France
- MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo TransferPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00884221 · 749 participants · Start Jul 2009 · Primary completion Jul 2010
Drug: Highly purified menotrophin; Recombinant FSH · For: Infertility
Sites: Anderlecht, Belgium; Brussels, Belgium; Edegem, Belgium · 25 sites in all
- FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)Pivotal-lookingCompleted
IBSA Institut Biochimique SAIndustry
NCT01969201 · 710 participants · Start Jan 2014 · Primary completion Jun 2016
Drug: Urofollitrophin; Follitrophin alpha · For: Infertility
Sites: Brussels, Belgium; Brescia, Italy; Milan, Italy · 16 sites in all
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist TreatmentPivotal-lookingRecruiting
Nanjing UniversityAcademic, hospital or other
NCT07128394 · 590 participants (planned) · Start Feb 1, 2024 · Primary completion Sep 30, 2026
Drug: Recombinant Luteinizing Hormone (rLH); Recombinant Follicle-Stimulating Hormone (rFSH) and 1 more · For: Infertility, Female; Luteinizing Hormone (LH)
Sites: Nanjing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea130
- headache83
- fatigue82
- off label use81
- vomiting53
- malaise43
- dizziness41
- pain41
- drug ineffective38
- blood thyroid stimulating hormone decreased28
- asthenia26
- pyrexia26
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 7 |
| 2006 | 14 |
| 2007 | 19 |
| 2008 | 13 |
| 2009 | 17 |
| 2010 | 24 |
| 2011 | 13 |
| 2012 | 20 |
| 2013 | 66 |
| 2014 | 61 |
| 2015 | 59 |
| 2016 | 66 |
| 2017 | 61 |
| 2018 | 40 |
| 2019 | 65 |
| 2020 | 49 |
| 2021 | 74 |
| 2022 | 76 |
| 2023 | 70 |
| 2024 | 102 |
| 2025 | 61 |
| 2026 | 46 |
Recalls
1 FDA enforcement reports for this application.
Feb 16, 2016 · Class II · Terminated
Presence of Particulate Matter: Glass particles found in the product after reconstitution.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Thyrogen (Thyrotropin Alfa)
2024 spending
$315K
Beneficiaries
70
74 claims
Per beneficiary
$4,503
$2,101.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $205,598 |
| 2021 | $259,926 |
| 2022 | $352,321 |
| 2023 | $398,120 |
| 2024 | $315,219 |
Part B: Thyrogen (Thyrotropin Alfa) · HCPCS J3240
2024 spending
$12.3M
Beneficiaries
2,930
4,912 claims
Per beneficiary
$4,215
2024 ASP limit $2,045.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,698,002 |
| 2021 | $11,030,313 |
| 2022 | $11,964,457 |
| 2023 | $12,139,009 |
| 2024 | $12,348,775 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.
Tchekmedyian V, Dunn L, Sherman E, et al. · Thyroid 2022 · Clinical Trial, Research Support, N.I.H., Extramural
- The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials.
Pak K, Cheon GJ, Kang KW, et al. · J Korean Med Sci 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
Mallick U, Harmer C, Yap B, et al. · N Engl J Med 2012 · Comparative Study, Multicenter Study
- [Use of 13-cis retinoic acid for treatment of advanced differentiated thyroid cancer].
Handkiewicz-Junak D, Roskosz J, Turska M, et al. · Wiad Lek 2001 · Clinical Trial, English Abstract
- [Pharmacological profiles and clinical effects of recombinant human thyrotropin alfa (Thyrogen) Intramuscular Injection 0.9 mg)].
Kishida H · Nihon Yakurigaku Zasshi 2009 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Ho AL, Grewal RK, Leboeuf R, et al. · N Engl J Med 2013 · Clinical Trial, Research Support, N.I.H., Extramural
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.